- Interpretable dimensionality reduction of single cell transcriptome data with deep generative models.
- The RNA-binding protein YBX1 regulates epidermal progenitors at a posttranscriptional level.
- Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
- Identification of cancer-associated missense mutations in hace1 that impair cell growth control and Rac1 ubiquitylation.
February 17, 2015
NSERC Brockhouse Prize For CycloMed99 17 February 2015 For their outstanding teamwork in realizing a solution for safe and reliable isotope production for hospitals in Canada, interdisciplinary research team CycloMed99 will be receiving a prestigious national award at a ceremony in Ottawa today. The Honourable David Johnston, Governor General of Canada, will present the NSERC Brockhouse Canada […]
Posted in Benard Lab, Media, News And Events | Tagged with BC Cancer Agency, BCCA, BCCRC, Benard, Brockhouse Prize, Cancer Research, Cyclotron, Francois Benard, Media, Medical Isotopes, NSERC, Radiology, Research, TRIUMF, UBC
January 8, 2015
Media Release | January 8, 2015 University of British Columbia scientists have shown that small cyclotrons – particle accelerators the size of an SUV – can replace hulking nuclear power plants as the country’s main source of medical isotopes, the radioactive atoms used for thousands of diagnostic scan across Canada each day. The demonstration last […]
June 11, 2013
BC breakthrough in isotope production for medical imaging. Dr Francois Benard and TRIUMF featured: CBC.ca, The Vancouver Sun, The Vancouver Province, The National Post, and on The CBC National (video). Medical isotopes: A made in B.C. solution Vancouver Sun Monday, June 10, 2013 By Erin Ellis Scientists in Vancouver have found a way to create […]
October 1, 2012
From the CIHR Annual Report 2011-12: “A team of researchers has found a way to produce the key medical isotope technetium-99m using cyclotrons. Tens of millions of medical procedures are conducted around the world each year using technetium-99m for detecting disease in the heart and bones, as well as elsewhere in the body. Two aging […]
February 28, 2012
The American Association for the Advancement of Science (AAAS) 2012 Annual Meeting wrapped up at the Vancouver Convention Centre on Monday. This scientific conference – the biggest of its kind – was a great opportunity for local researchers to shine, and two of our department’s Principal Investigators were among the Vancouver-based scientists invited to speak […]
January 24, 2011
New federal investments in BC Cancer Agency and TRIUMF will enable augmenting local supply of key medical isotope Vancouver—The Government of Canada today announced a $6 million investment to develop an alternative medical-isotope production technology proposed by TRIUMF and the BC Cancer Agency (BCCA). The team will leverage existing capabilities at TRIUMF and BCCA to […]
November 28, 2009
The world is facing a shortage of the key medical isotope Technetium-99m (Tc-99m). More than 80% of the estimated 1.5 million nuclear medicine procedures performed annually in Canada use radiopharmaceuticals based on this isotope, which is currently produced using nuclear reactors. Together with TRIUMF and other partners, the BC Cancer Agency (BCCA) has received a […]